Clinical trial · Observational
CIRSE Registry for SIR-Spheres in France (CIRT-FR)
NCT03256994CI-TRIAL-00111355CIRT-FRcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, is a minimal invasive, endovascular treatment for primary and secondary liver tumours. In France, SIR-Spheres are listed as reimbursable by the national health authorities (Haute Autorité de Santé \[HAS\]). In order to evaluate the reimbursement after five years, all patients treated with SIR-Spheres will be entered into a registry that collects data on the real-life clinical application of SIRT and reports to the national authorities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| QLQ-C30 with HCC module | Behavioral | — | UNRESOLVED |
| Yttrium-90 loaded SIR-Spheres microspheres | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Description of the clinical context in which SIR-Spheres are applied
- timeFrame
- Baseline, follow-up every 3 months until 24 months
- description
- Context of systemic therapy; intention of treatment; prior hepatic procedures; post hepatic procedures
Secondary outcomes (5)
- measure
- Adverse events, treatment complications and laboratory assessments
- timeFrame
- Follow-up every 3 months until 24 months
- description
- Adverse events measured according to CTCAE 4.03, treatment complications reported bz investigators and abnormal laboratory assessments according to CTCAE 4.03
- measure
- Effectiveness
- timeFrame
- Follow-up every 3 months until 24 months
- description
- Based on overall survival (OS), progression free survival (PFS), liver specific PFS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years or older * Primary or secondary liver tumours * Treatment of liver tumours with SIR-Spheres * Signed informed consent form Exclusion Criteria: \- Consent denied
References
Publications (4)
- RESULTRonot M, Loffroy R, Arnold D, Greget M, Sengel C, Pinaquy JB, Pellerin O, Maleux G, Peynircioglu B, Pelage JP, Schaefer N, Sangro B, de Jong N, Zeka B, Urdaniz M, Helmberger T, Vilgrain V. Transarterial Radioembolisation with Y90 Resin Microspheres and the Effect of Reimbursement Criteria in France: Final Results of the CIRT-FR Prospective Observational Study. Cardiovasc Intervent Radiol. 2025 Feb;48(2):205-220. doi: 10.1007/s00270-024-03955-y. Epub 2025 Jan 14. PMID 39809885
- RESULTLoffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, Tselikas L, Arnold D, Maleux G, Pelage JP, Pellerin O, Peynircioglu B, Sangro B, Schaefer N, Urdaniz M, Kaufmann N, Bilbao JI, Helmberger T, Vilgrain V; CIRT-FR Principal Investigators. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. Cardiovasc Intervent Radiol. 2021 Jan;44(1):36-49. doi: 10.1007/s00270-020-02643-x. Epub 2020 Sep 25. PMID 32975600
- RESULTReimer P, Vilgrain V, Arnold D, Balli T, Golfieri R, Loffroy R, Mosconi C, Ronot M, Sengel C, Schaefer N, Maleux G, Munneke G, Peynircioglu B, Sangro B, Kaufmann N, Urdaniz M, Pereira H, de Jong N, Helmberger T. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies. Cardiovasc Intervent Radiol. 2024 Mar;47(3):310-324. doi: 10.1007/s00270-023-03657-x. Epub 2024 Feb 6. PMID 38321223
- RESULTAuthors: Thomas Helmberger, Dirk Arnold, Romaric Loffroy, Maxime Ronot, Bruno Sangro, Frank Kolligs, Olivier Pellerin, Geert Maleux, Bora Peynircioglu, Niklaus Schaefer, Jose Ignacio Bilbao, Niels de Jong, Milan Geyer, Bleranda Zeka, Maria Urdaniz, Valerie Vilgrain Article Title: Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies Journal Name: CVIR Oncology Publication Date: 2026 Volume number: 2:5